It was shown that relaxin-2 is a direct downstream target of R273H p53 mutation in prostate carcinoma cells [23], and relaxin expression is up-regulated by androgen withdrawal in vitro and in vivo [24]. This evidence concerns the gene TP53 and prostate carcinoma.